Immatics
TCR-T company whose PRAME-directed anzu-cel (IMA203) is in the phase 3 SUPRAME trial in melanoma, with a launch targeted for 2027.
Anzu-cel showed 54% confirmed ORR and 12.1-month median duration of response in PD-1-pretreated melanoma (phase 1b). SUPRAME (PFS primary endpoint) is on track to complete randomisation by end-2026 with interim/final analysis expected to trigger in 2026. Also developing TCR bispecifics (TCER).
Pages like this
not linked directly; found by shared links- IdeaTCR therapeutics for non-HLA-A*02 patients
Shares PRAME, TCR-T cell therapy, Melanoma.
- CompanyTScan Therapeutics
Shares Antibodies that see mutant KRAS and p53 fragments displayed on the cell surface, TCR-T cell therapy.
- CompanyImmunocore
Shares Antibodies that see mutant KRAS and p53 fragments displayed on the cell surface, PRAME, Melanoma.
- TermHLA-A*02:01 restriction
Shares PRAME, TCR-T cell therapy, Sarcomas (soft tissue, bone, GIST), Melanoma.
- TrialIGNYTE-ESO
Shares TCR-T cell therapy, Sarcomas (soft tissue, bone, GIST).
- TrialPRISM-MEL-301
- PersonPatrick Hwu
Shares TCR-T cell therapy, Melanoma.
- ProductAfamitresgene autoleucel
Shares Comprehensive Cancer Center Tübingen-Stuttgart, TCR-T cell therapy, Sarcomas (soft tissue, bone, GIST).